Beam Therapeutics (BEAM) Stock Price
Beam Therapeutics Price
Beam Therapeutics (BEAM) Stock | ISIN US07373V1052 | WKN A2PY7P. The current Beam Therapeutics stock price is 31.01 USD (2026). Revenue is 49.82 M USD. Net income is -479.02 M USD. The P/E ratio is -6.4. Market capitalization is 3.16 B USD. Beam Therapeutics operates in the Health sector.
Beam Therapeutics stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Beam Therapeutics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Beam Therapeutics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Beam Therapeutics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Beam Therapeutics Price |
|---|
Beam Therapeutics Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Beam Therapeutics Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Beam Therapeutics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Beam Therapeutics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Beam Therapeutics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Beam Therapeutics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Beam Therapeutics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Beam Therapeutics stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Beam Therapeutics Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Beam Therapeutics business model & stock analysis
Beam Therapeutics SWOT Analysis
Strengths
Beam Therapeutics Inc is equipped with advanced gene editing technologies such as base editing and prime editing, which enable precise modifications to genetic material. This positions the company at the forefront of the gene therapy industry, offering potential treatments for a wide range of genetic diseases.
Beam Therapeutics holds a robust intellectual property portfolio, including numerous patents related to its gene editing technologies. This creates a barrier to entry for competitors and provides the company with long-term exclusivity, enhancing its competitive advantage in the market.
The company is comprised of a talented team of scientists, researchers, and industry experts who possess extensive knowledge and expertise in gene editing and therapeutic development. Their collective skills contribute to the successful execution of Beam Therapeutics' projects and drive innovation within the organization.
Beam Therapeutics has established strategic collaborations and partnerships with leading academic institutions and pharmaceutical companies. These alliances provide access to additional resources, technologies, and expertise, enabling the company to accelerate research and development efforts and expand its product pipeline.
Weaknesses
At present, Beam Therapeutics has a relatively limited product portfolio, with only a few candidates in various stages of development. This restricts the company's revenue potential and increases its dependency on the success of a limited number of therapeutic programs.
As with any gene editing technology, Beam Therapeutics faces regulatory and ethical challenges associated with the use of such technologies in human therapies. The company needs to navigate complex regulatory frameworks and address public concerns surrounding gene manipulation, which could potentially delay product approvals or limit market acceptance.
The gene therapy market is highly competitive, with numerous companies actively pursuing gene editing technologies and therapeutic solutions. Beam Therapeutics faces the challenge of differentiating itself from competitors, both in terms of technological advancements and market positioning, to capture and maintain significant market share.
Opportunities
The demand for gene therapies is expected to increase as the understanding of genetic diseases expands and the need for targeted treatment options becomes more apparent. Beam Therapeutics has the opportunity to leverage its expertise and technology to develop novel therapies to address unmet medical needs.
The versatility of Beam Therapeutics' gene editing technologies allows the company to explore and expand its presence in various therapeutic areas beyond its current focus. By diversifying its product pipeline, the company can tap into new markets and address a wider range of genetic diseases.
Threats
Gene editing technologies, although promising, may carry inherent risks and safety concerns. Any adverse events or unexpected outcomes related to the use of Beam Therapeutics' therapies could lead to setbacks in clinical trials, regulatory challenges, or loss of public trust, impacting the company's overall success.
The biotechnology sector, including gene therapy companies like Beam Therapeutics, often face market volatility influenced by factors such as regulatory changes, healthcare policies, economic conditions, and investor sentiment. Fluctuations in the market can impact the company's financial stability, ability to raise funds, and investor confidence.
Reimbursement for gene therapies is still evolving, and uncertain reimbursement models can pose challenges for the adoption and commercialization of innovative treatments. Beam Therapeutics needs to carefully navigate the reimbursement landscape to ensure adequate pricing and reimbursement coverage for its therapies.
Beam Therapeutics Segments
Beam Therapeutics Eulerpool Fair Value
Beam Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio
Beam Therapeutics annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Beam Therapeutics shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Beam Therapeutics Dividend History
10 years of dividend payments
Beam Therapeutics Earnings Estimates
Beam Therapeutics Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 5/12/2026 | -1.12USD | 11.2 MUSD | 2026 Q1 |
| 5/4/2026 | -1.12USD | 11.2 MUSD | 2026 Q1 |
| 3/3/2026 | -1.01USD | 12.82 MUSD | 2025 Q4 |
| 2/23/2026 | -1USD | 13.04 MUSD | 2025 Q4 |
| 11/6/2024 | -1.16USD | 15.78 MUSD | 2024 Q3 |
| 5/8/2024 | -1.15USD | 21.59 MUSD | 2024 Q1 |
| 2/26/2024 | -0.98USD | 20.31 MUSD | 2023 Q4 |
| 8/7/2023 | -1.47USD | 7.23 MUSD | 2023 Q2 |
| 5/8/2023 | -1.41USD | 7.23 MUSD | 2023 Q1 |
| 2/27/2023 | -1.37USD | 13.99 MUSD | 2022 Q4 |
EESG©
Eulerpool ESG Scorecard© for the Beam Therapeutics stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Beam Therapeutics shareholder structure
| % | Name |
|---|---|
12.23953% | |
11.1884% | |
9.87935% | |
9.00281% | |
6.86473% | |
5.13305% | |
4.45723% | |
4.32878% | |
2.55323% | |
2.39565% |
Beam Therapeutics Executives and Management Board
Mr. John Evans
(47)Chief Executive Officer, Principal Accounting Officer, Director · since 2017
Mr. Sravan Emany
(47)Chief Financial and Principal Financial Officer
Dr. Giuseppe Ciaramella
(56)President
Dr. Amy Simon
(61)Chief Medical Officer
Dr. Christine Bellon
(60)Chief Legal Officer and Secretary
Beam Therapeutics Supply Chain
Frequently asked questions about Beam Therapeutics
Beam Therapeutics Inc's business model revolves around developing and commercializing precision genetic medicines using its proprietary base editing technology platform. By leveraging CRISPR technology, Beam aims to correct errors at the molecular level by making precise changes to the DNA code, allowing for the treatment of a wide range of diseases. By focusing on a diverse pipeline of therapeutics across multiple disease areas, Beam Therapeutics Inc aims to transform the landscape of genetic medicine and provide innovative solutions for patients in need.
Beam Therapeutics stock
Beam Therapeutics Peer Group
Beam Therapeutics Ticker
Beam Therapeutics FIGI
All fundamentals and in-depth analysis of Beam Therapeutics
Our stock analysis for Beam Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Beam Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.